CO7240370A2 - Forma farmaceútica para la liberación prolongada de sustancias activas - Google Patents
Forma farmaceútica para la liberación prolongada de sustancias activasInfo
- Publication number
- CO7240370A2 CO7240370A2 CO15007539A CO15007539A CO7240370A2 CO 7240370 A2 CO7240370 A2 CO 7240370A2 CO 15007539 A CO15007539 A CO 15007539A CO 15007539 A CO15007539 A CO 15007539A CO 7240370 A2 CO7240370 A2 CO 7240370A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutical form
- active substances
- prolonged release
- active substance
- release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Abstract
Se describe una forma farmacéutica, que hace posible liberar uniformemente una sustancia activa durante un período de tiempo prolongado. La forma farmacéutica comprende un emulsionante con un motivo estructura de óxido de polialquileno. La forma farmacéutica es adecuada para liberar una segunda sustancia activa junto con la primera sustancia activa. Se obtiene una liberación uniforme aun cuando dos sustancias activas tienen propiedades completamente diferentes en términos de solubilidad. También se describe un método para la producción de la forma farmacéutica y su uso.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102012105512.2A DE102012105512A1 (de) | 2012-06-25 | 2012-06-25 | Arzneiform zur verlängerten Freisetzung von Wirkstoffen |
Publications (1)
Publication Number | Publication Date |
---|---|
CO7240370A2 true CO7240370A2 (es) | 2015-04-17 |
Family
ID=48670585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO15007539A CO7240370A2 (es) | 2012-06-25 | 2015-01-15 | Forma farmaceútica para la liberación prolongada de sustancias activas |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP2863891B1 (es) |
KR (1) | KR102160837B1 (es) |
AU (1) | AU2013283474B2 (es) |
BR (1) | BR112014032583B1 (es) |
CA (1) | CA2876294C (es) |
CO (1) | CO7240370A2 (es) |
DE (1) | DE102012105512A1 (es) |
EA (2) | EA035815B1 (es) |
ES (1) | ES2817248T3 (es) |
HR (1) | HRP20201534T1 (es) |
HU (1) | HUE050945T2 (es) |
IL (1) | IL236465B (es) |
IN (1) | IN2014MN02511A (es) |
LT (1) | LT2863891T (es) |
MX (1) | MX371143B (es) |
PH (1) | PH12014502834A1 (es) |
PL (1) | PL2863891T3 (es) |
PT (1) | PT2863891T (es) |
RS (1) | RS60872B1 (es) |
SI (1) | SI2863891T1 (es) |
UA (1) | UA116776C2 (es) |
WO (1) | WO2014001268A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015023675A2 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
LT2959887T (lt) * | 2014-06-26 | 2019-03-12 | Hennig Arzneimittel Gmbh&Co. Kg | Vaistai galvos svaigimo, atsiradusio dėl įvairių priežasčių, gydymui |
WO2016010771A1 (en) | 2014-07-17 | 2016-01-21 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
JP2017531026A (ja) | 2014-10-20 | 2017-10-19 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 徐放性乱用抑止性液体充填剤形 |
KR101625344B1 (ko) * | 2015-12-21 | 2016-06-08 | 주식회사 유영제약 | 세레콕시브 및 둘록세틴을 함유하는 약제학적 조성물 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
IE80467B1 (en) * | 1995-07-03 | 1998-07-29 | Elan Corp Plc | Controlled release formulations for poorly soluble drugs |
DE69811233T2 (de) * | 1997-10-27 | 2003-11-20 | Merck Patent Gmbh | Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes |
US6368622B2 (en) * | 1999-01-29 | 2002-04-09 | Abbott Laboratories | Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
CA2551254A1 (en) * | 2003-12-31 | 2005-07-21 | Pfizer Products Inc. | Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers |
US20050281876A1 (en) * | 2004-06-18 | 2005-12-22 | Shun-Por Li | Solid dosage form for acid-labile active ingredient |
DE102005014141B4 (de) * | 2005-03-23 | 2006-12-21 | Hennig Arzneimittel Gmbh & Co. Kg | Tablettenförmige Retardzubereitung gegen Schwindel |
WO2007056078A2 (en) | 2005-11-02 | 2007-05-18 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
WO2007086078A2 (en) * | 2006-01-30 | 2007-08-02 | Panacea Biotec Ltd. | Novel pharmaceutical compositions and process of preparation thereof |
CN101049309A (zh) * | 2006-04-03 | 2007-10-10 | 陈茜 | 桂利嗪滴丸及其制备方法 |
PL2200588T3 (pl) * | 2007-09-25 | 2019-09-30 | Solubest Ltd. | Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania |
AU2008334580A1 (en) * | 2007-12-12 | 2009-06-18 | Basf Se | Salts of active ingredients with polymeric counter-ions |
US20120134921A1 (en) * | 2009-06-11 | 2012-05-31 | Photocure Asa | Solid compositions comprising 5-aminolevulinic acid |
WO2011024029A1 (en) * | 2009-08-24 | 2011-03-03 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Fast disintegrating dosage forms of cinnarizine and dimenhydrinate combination |
DE102011051308A1 (de) * | 2011-06-24 | 2012-12-27 | Hennig Arzneimittel Gmbh & Co. Kg | Herstellungsverfahren und Arzneiform |
DE102011051304A1 (de) * | 2011-06-24 | 2012-12-27 | Hennig Arzneimittel Gmbh & Co. Kg | Wirkstoffmatrix |
DE102011053068A1 (de) * | 2011-08-29 | 2013-02-28 | Hennig Arzneimittel Gmbh & Co. Kg | Darreichungsform mit stabilisierten Wirkstoffpartikeln |
-
2012
- 2012-06-25 DE DE102012105512.2A patent/DE102012105512A1/de not_active Ceased
-
2013
- 2013-06-24 EP EP13730598.3A patent/EP2863891B1/de active Active
- 2013-06-24 RS RS20201085A patent/RS60872B1/sr unknown
- 2013-06-24 CA CA2876294A patent/CA2876294C/en active Active
- 2013-06-24 MX MX2014015642A patent/MX371143B/es active IP Right Grant
- 2013-06-24 SI SI201331778T patent/SI2863891T1/sl unknown
- 2013-06-24 BR BR112014032583-9A patent/BR112014032583B1/pt active IP Right Grant
- 2013-06-24 HU HUE13730598A patent/HUE050945T2/hu unknown
- 2013-06-24 PT PT137305983T patent/PT2863891T/pt unknown
- 2013-06-24 PL PL13730598T patent/PL2863891T3/pl unknown
- 2013-06-24 UA UAA201500503A patent/UA116776C2/uk unknown
- 2013-06-24 AU AU2013283474A patent/AU2013283474B2/en active Active
- 2013-06-24 LT LTEP13730598.3T patent/LT2863891T/lt unknown
- 2013-06-24 WO PCT/EP2013/063163 patent/WO2014001268A1/de active Application Filing
- 2013-06-24 IN IN2511MUN2014 patent/IN2014MN02511A/en unknown
- 2013-06-24 ES ES13730598T patent/ES2817248T3/es active Active
- 2013-06-24 EA EA201792143A patent/EA035815B1/ru unknown
- 2013-06-24 KR KR1020147036365A patent/KR102160837B1/ko active IP Right Grant
- 2013-06-24 EA EA201500043A patent/EA028064B1/ru not_active IP Right Cessation
-
2014
- 2014-12-19 PH PH12014502834A patent/PH12014502834A1/en unknown
- 2014-12-25 IL IL236465A patent/IL236465B/en active IP Right Grant
-
2015
- 2015-01-15 CO CO15007539A patent/CO7240370A2/es unknown
-
2020
- 2020-09-25 HR HRP20201534TT patent/HRP20201534T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
RS60872B1 (sr) | 2020-11-30 |
BR112014032583B1 (pt) | 2022-05-17 |
LT2863891T (lt) | 2020-12-10 |
EP2863891B1 (de) | 2020-08-26 |
CA2876294A1 (en) | 2014-01-03 |
KR20150041612A (ko) | 2015-04-16 |
BR112014032583A2 (pt) | 2017-06-27 |
PH12014502834B1 (en) | 2015-02-02 |
MX2014015642A (es) | 2015-08-05 |
ES2817248T3 (es) | 2021-04-06 |
PT2863891T (pt) | 2020-09-25 |
EP2863891A1 (de) | 2015-04-29 |
DE102012105512A1 (de) | 2014-04-24 |
MX371143B (es) | 2020-01-20 |
EA028064B1 (ru) | 2017-10-31 |
EA035815B1 (ru) | 2020-08-14 |
UA116776C2 (uk) | 2018-05-10 |
CA2876294C (en) | 2020-09-08 |
PH12014502834A1 (en) | 2015-02-02 |
HUE050945T2 (hu) | 2021-01-28 |
SI2863891T1 (sl) | 2020-11-30 |
EA201500043A1 (ru) | 2015-09-30 |
AU2013283474A1 (en) | 2015-01-29 |
IN2014MN02511A (es) | 2015-07-17 |
IL236465B (en) | 2020-06-30 |
BR112014032583A8 (pt) | 2021-06-22 |
KR102160837B1 (ko) | 2020-09-29 |
HRP20201534T1 (hr) | 2021-02-19 |
PL2863891T3 (pl) | 2021-01-25 |
IL236465A0 (en) | 2015-02-26 |
EA201792143A1 (ru) | 2018-05-31 |
WO2014001268A1 (de) | 2014-01-03 |
AU2013283474B2 (en) | 2017-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO7240370A2 (es) | Forma farmaceútica para la liberación prolongada de sustancias activas | |
CY1123515T1 (el) | Μεθοδοι αγωγης μιας ταυπαθειας | |
CY1121712T1 (el) | Γελη λυματος αιμοπεταλιων | |
CL2012003075A1 (es) | Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. | |
CL2014000370A1 (es) | Hemifumarato de tenofovir alafenamida; metodo de preparación; composicion farmaceutica que lo comprende; metodo para preparar la composicion farmaceutica; y uso en el tratamiento de una infeccion por hiv. | |
CL2014003232A1 (es) | Formulaciones y métodos para la administración vaginal de antiprogestinas. | |
CL2015000294A1 (es) | Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor del receptor del factor de crecimiento epidermico y opcionalmente un inhibidor pi3halpha y uso en el tratamiento de una enfermedad proliferativa. | |
UY34651A (es) | ?formas de dosificación de liberación inmediata resistentes a la manipulación, procesos para prepararlas, métodos y usos de las mismas?.. | |
CR20130033A (es) | Formulaciones de rifaximina y usos de las mismas | |
PH12015502535A1 (en) | Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes | |
CL2013000718A1 (es) | Un complejo de inclusion que comprende a) una ciclodextrina, b) fulvestrant y c) un portador; su metodo de preparacion; formulacion y forma de dosificacion que comprende al complejo; preparacion que comprende al complejo o a la formulación; y su uso en el tratamiento del cancer y lupus eritematoso sistemico, entre otras enfermedades. | |
GT201200304A (es) | Composiciones farmacéuticas que comprenden hidromorfona y naloxona | |
IN2014MN02214A (es) | ||
EP3399963A4 (en) | Gel compositions for transdermal administration for maximizing drug concentration in the stratum corneum and serum and method of using the same | |
UY34008A (es) | ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?. | |
CL2015000254A1 (es) | Vesículas que comprenden factor de crecimiento epidermico (egf); proceso de preparación; composición farmacéutica que las comprende; y uso para tratar heridas complejas . | |
CL2014000267A1 (es) | Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina; kit farmaceutico; metodo para prevenir o tratar la inflamacion. | |
UY34786A (es) | Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo | |
CL2015001748A1 (es) | Formulaciones antiparasitarias transdermicas | |
AU343717S (en) | Sticking plaster used for medical purposes | |
CL2014001399A1 (es) | Compuestos de reversion anticoagulante; composicion farmaceutica y el uso de los mismos para revertir el efecto anticoagulante de un inhibidor de la coagulacion. | |
CL2014002470A1 (es) | Marcadores moleculares de bajo contenido de ácido palmítico en girasol (helianthus annus), y los metodos de uso de los mismos | |
UY34552A (es) | Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen | |
BR112013019924A2 (pt) | composições para cuidado oral | |
CY1122538T1 (el) | Συμπλεγματα χονδροϊτινης για διαδερμικη απορροφηση |